Federated Hermes, Inc. Century Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	SELL	$2.46 - $4.05 $833,890 - $1.37 Million	-338,980 Reduced 55.11%	276,163 $704,000
Q1 2024 May 14, 2024	SELL	$3.19 - $5.32 $10,651 - $17,763	-3,339 Reduced 0.54%	615,143 $2.57 Million
Q4 2023 Jan 31, 2024	BUY	$1.28 - $3.32 $3,200 - $8,300	2,500 Added 0.41%	618,482 $2.05 Million
Q3 2023 Nov 13, 2023	BUY	$2.0 - $3.23 $3,776 - $6,098	1,888 Added 0.31%	615,982 $1.23 Million
Q2 2023 Aug 14, 2023	SELL	$2.91 - $3.53 $1.6 Million - $1.94 Million	-550,517 Reduced 47.27%	614,094 $1.94 Million
Q1 2023 May 08, 2023	BUY	$3.4 - $5.11 $537 - $807	158 Added 0.01%	1,164,611 $4.04 Million
Q4 2022 Feb 13, 2023	BUY	$4.84 - $11.58 $1,737 - $4,157	359 Added 0.03%	1,164,453 $5.97 Million
Q3 2021 Nov 15, 2021	BUY	$20.8 - $31.93 $12.8 Million - $19.6 Million	614,094 Added 111.65%	1,164,094 $29.3 Million
Q2 2021 Aug 16, 2021	BUY	$22.45 - $29.34 $12.3 Million - $16.1 Million	550,000 New	550,000 $16.1 Million

36.9M

8.7K

10.2K

Ticker IPSC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,881,800
Market Cap $71.2M
Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.